biote Corp.

BTMD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Operating Activities
Net Income $27.0M $3.2M $3.3M $-969.0K $11.1M
Depreciation & Amortization $3.7M $3.6M $3.0M $2.2M $1.4M
Depreciation $800.0K $800.0K $1.2M $713.0K
Amortization $1.2M $1.2M
Stock-Based Compensation $8.9M $8.7M $9.1M $82.2M
Net Cash from Operating Activities $35.2M $45.2M $26.9M $-9.2M $33.7M
Investing Activities
Capital Expenditures $5.0M $6.4M $359.0K $333.0K $1.4M
Business Acquisitions $11.8M
Net Cash from Investing Activities $-6.9M $-18.8M $-2.7M $-1.8M $-3.8M
Financing Activities
Dividends Paid $1.7M $4.7M $8.7M $12.9M $11.4M
Stock Repurchases $3.4M $5.6M
Net Cash from Financing Activities $-43.6M $-76.1M $-14.4M $63.5M $-20.3M
Net Change in Cash $-15.2M $-49.7M $9.8M $52.5M $128.8K
Free Cash Flow $30.2M $38.8M $26.5M $-9.5M $32.3M